B6-hTREM1 Mouse
Product Name
B6-hTREM1 Mouse
Product ID
C001790
Strain Name
C57BL/6NCya-Trem1tm1(hTREM1)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hTREM1 Mouse (Catalog C001790) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TREM1
Gene Alias
CD354, TREM-1
NCBI ID
Chromosome
Chr 6 (Human)
MGI ID
Datasheet
Strain Description
The Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) gene encodes a transmembrane protein, also known as CD354, primarily expressed on myeloid cells such as neutrophils, monocytes, and macrophages, with expression also observed in dendritic cells, microglia, osteoclasts, platelets, and even some epithelial and endothelial cells [1]. Upon activation, the TREM1 protein amplifies inflammatory responses, often synergizing with Toll-like receptor (TLR) and NOD-like receptor (NLR) signaling pathways. This leads to the robust production and release of pro-inflammatory cytokines and chemokines, enhanced degranulation, phagocytosis, and respiratory burst in neutrophils and macrophages, and even promotes dendritic cell maturation [2]. A soluble form of TREM1 (sTREM1) also exists, which can act as a decoy receptor to modulate inflammation and serves as a biomarker for various inflammatory conditions [3]. Dysregulated TREM1 activity is implicated in a wide range of diseases, including infectious diseases like sepsis and pneumonia, chronic inflammatory conditions such as inflammatory bowel disease, atherosclerosis, rheumatoid arthritis, and various cancers (e.g., glioma, hepatocellular carcinoma, lung adenocarcinoma, breast, colon, and pancreatic cancers), as well as neurodegenerative disorders like Parkinson's and Alzheimer's disease, and kidney-related diseases [2-5].
The B6-hTREM1 mouse is a humanized model, constructed by replacing the mouse Trem1 signal peptide (aa. 1-20) and endogenous extracellular domain (aa. 21-202) with the human TREM1 signal peptide (aa. 1-20) and extracellular domain (aa. 21-205), while preserving the murine aa. 203-230. B6-hTREM1 mice can be used for research into the pathogenesis of various inflammatory diseases, cancers, neurodegenerative diseases, and kidney-related diseases, as well as for the screening, development, and safety evaluation of TREM1-targeted drugs.
Reference
Li C, Cai C, Xu D, Chen X, Song J. TREM1: Activation, signaling, cancer and therapy. Pharmacol Res. 2024 Jun;204:107212.
Li H, Yu W, Zheng X, Zhu Z. TREM1-Microglia crosstalk: Neurocognitive disorders. Brain Res Bull. 2025 Jan;220:111162.
Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M. sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol. 2021 Aug;18(8):2054-2056.
Siskind S, Brenner M, Wang P. TREM-1 Modulation Strategies for Sepsis. Front Immunol. 2022 Jun 15;13:907387.
Fan Y, Xu Y, Huo Z, Zhang H, Peng L, Jiang X, Thomson AW, Dai H. Role of triggering receptor expressed on myeloid cells-1 in kidney diseases: A biomarker and potential therapeutic target. Chin Med J (Engl). 2024 Jul 20;137(14):1663-1673.
Strain Strategy
The mouse Trem1 signal peptide (aa.1~20) and endogenous extracellular domain will be replaced with the human TREM1 signal peptide and extracellular domain. The mouse Gm18679 will be affected in this strategy.
Figure 1. Gene editing strategy of B6-hTREM1 mice.
Application Area
TREM1-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA);
Research on the pathological mechanisms and therapeutic approaches of cancers such as glioma and hepatocellular carcinoma;
Research on the pathological mechanisms and therapeutic approaches of neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD).
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
